Sean Koh, MD
Ophthalmology · Atlanta, GANPI 1588667620
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $28,868 of the $37,108 with a category attached, or 77.8%. US Retina LLC accounts for 77.8% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2021 at $14,087 and has fallen 92.2% since, to $1,093 in 2025. Among ophthalmology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $189.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$29K
- Regeneron Healthcare Solutions, Inc.$2K
- Genentech USA, Inc.$1K
- Alimera Sciences, Inc.$998
- Apellis Pharmaceuticals, Inc.$931
- AbbVie$688
- plus $3K from 13 others
Across 1 payment — averaging $30.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$30
What the payments were for
- Food & beverage$8,22322%
- Education$170%
- Ownership interest$28,86878%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $28,868 |
| Regeneron Healthcare Solutions, Inc. | 48 | $1,764 |
| Genentech USA, Inc. | 31 | $1,332 |
| Alimera Sciences, Inc. | 26 | $998 |
| Apellis Pharmaceuticals, Inc. | 21 | $931 |
| AbbVie(2 entities) | 22 | $688 |
| Novartis | 8 | $473 |
| ANI Pharmaceuticals, Inc. | 8 | $472 |
| Astellas Pharma US Inc | 8 | $390 |
| Alcon | 3 | $314 |
| Bausch & Lomb Americas Inc. | 3 | $309 |
| Biogen | 2 | $137 |
| Genentech, Inc. | 1 | $127 |
| Regeneron | 1 | $123 |
| Eyepoint US, Inc. | 3 | $50 |
| Coherus Oncology, Inc. | 2 | $48 |
| Sandoz | 1 | $35 |
| Teleflex LLC | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,108 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 71 | $3,710 |
| Atropine Sulfate | 29 | $1,142 |
| Latanoprost | 40 | $658 |
| Timolol Maleate | 74 | $585 |
| Ciprofloxacin Hcl | 34 | $455 |
| Acetazolamide ErAcetazolamide | 11 | $337 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $197 |
| Prednisone | 15 | $107 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Atlanta
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Evan SchoenbergAtlanta$130K
- Robert StultingAtlanta$85K
- David SackelAtlanta$82K
- Atul SharmaAtlanta$77K
- Daniel MartinAtlanta$55K
- Douglas DayAtlanta$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.